Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depth of Botulinum Neurotoxin Injection for Glabellar Lines
NCT05766683Phase 1Active, not recruiting
- Sponsor
- Henry Ford Health
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of botulinum toxin type A in glabellar rhytides (2 arms), sponsored by Henry Ford Health. Primary endpoint: Improvement of glabellar lines at 120 days. Started Mar 2023; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT05766683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766683.